Skip to main content
Michele Redell, MD, Pediatric Hematology & Oncology, Houston, TX

MicheleSimmonsRedellMD

Pediatric Hematology & Oncology Houston, TX

Assistant Professor, Pediatrics, Baylor College of Medicine

Dr. Redell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Redell's full profile

Already have an account?

  • Office

    6701 Fannin St
    Houston, TX 77030
    Phone+1 832-822-4240
    Fax+1 832-825-4247

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2001 - 2004
  • Baylor College of Medicine (Houston)
    Baylor College of Medicine (Houston)Residency, Pediatrics, 1998 - 2001
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 1998
  • University of Washington
    University of WashingtonPh.D., Pharmacology, 1996
  • Brown University
    Brown UniversitySc.B., Neural Science, 1988

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2002 - 2025
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Chief Fellow Pediatric Hematology-Oncology, Baylor College of Medicine, 2003

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Drug Targeting of NR4A Nuclear Receptors for Treatment of Acute Myeloid Leukemia  
    Michele Redell, MD, Nature
  • Ligand-induced Stat3 signaling increases at relapse and is associated with outcome in pediatric AML: A Report from the Children’s Oncology Group  
    Stevens, A.M., Ruiz, M.J, Gerbing, R.B., Alonzo, T.A., Gamis, A. and Redell, M.S., Haematologica, 1/1/2015
  • Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity  
    Minus, M., Liu, W., Vohidov, F., Kasembeli, M., Long, X., Krueger, M., Stevens, A., Kolosov, M., Sison, E., Tweardy, D., Redell, M. and Ball, Z., Angew. Chemie., 1/1/2015
  • Join now to see all

Abstracts/Posters

  • Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia in the Contemporary Era
    Michele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia
    Michele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML
    Michele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Grant Support

  • STAT3 Isoforms In Maturation And Survival Of Normal And Malignant Myeloid CellsNational Heart, Lung, And Blood Institute2008–2011